Content about Diabetes mellitus type 2

April 3, 2014

MannKind Corp. on Tuesday announced that the Endocrinologic and Metabolic Drugs Advisory Committee of the Food and Drug Administration voted 13-to-1 to recommend that Afrezza (insulin human [rDNA origin]) inhalation powder be granted marketing approval by the FDA to improve glycemic control in adults with Type 1 diabetes and voted 14-to-0 to recommend that Afrezza be granted marketing approval by the FDA to improve glycemic control in adults with Type 2 diabetes.

VALENCIA, Calif. — MannKind Corp. on Tuesday announced that the Endocrinologic and Metabolic Drugs Advisory Committee of the Food and Drug Administration voted 13-to-1 to recommend that Afrezza (insulin human [rDNA origin]) inhalation powder be granted marketing approval by the FDA to improve glycemic control in adults with Type 1 diabetes and voted 14-to-0 to recommend that Afrezza be granted marketing approval by the FDA to improve glycemic control in adults with Type 2 diabetes. 

January 23, 2014

Mylan announced that its U.S.-based subsidiary has launched repaglinide tablets, a generic version of Novo Nordisk's Prandin.

PITTSBURGH — Mylan on Thursday announced that its subsidiary has launched repaglinide tablets, a generic version of Novo Nordisk's Prandin. The drug is used to improve glycemic control in adults with Type 2 diabetes mellitus.

Repaglinide tablets in 0.5 mg, 1 mg and 2 mg had sales in the United States of approximately $212.95 million for the 12 months ending Sept. 30, 2013, according to IMS Health.

 

January 8, 2014

Older patients at high risk for heart disease who follow a Mediterranean diet rich in extra-virgin olive oil do not need to restrict calories, increase exercise or lose weight to prevent diabetes, according to an article being published in Annals of Internal Medicine that was released Monday.

PHILADELPHIA — Older patients at high risk for heart disease who follow a Mediterranean diet rich in extra-virgin olive oil do not need to restrict calories, increase exercise or lose weight to prevent diabetes, according to an article being published in Annals of Internal Medicine that was released Monday. 

October 3, 2013

Research Now announced the launch of its Diabetes Panel, a collection of 336,000 deeply-profiled panelists in the United States and Canada who have been diagnosed with Type 1 diabetes, Type 2 diabetes, high blood pressure or obesity.

PLANO, Texas — Research Now announced the launch of its Diabetes Panel, a collection of 336,000 deeply-profiled panelists in the United States and Canada who have been diagnosed with Type 1 diabetes, Type 2 diabetes, high blood pressure or obesity. Research Now's Healthcare Panels also include physicians, nurses, pharmacists, hospital executives and administrators.

September 11, 2013

Nearly all doctors say that the sharp growth in Type 2 diabetes around the world and the obesity epidemic are linked to excess sugar consumption, according to a new report by the Credit Suisse Research Institute.

NEW YORK — Nearly all doctors say that the sharp growth in Type 2 diabetes around the world and the obesity epidemic are linked to excess sugar consumption, according to a new report by the Credit Suisse Research Institute.

The institute, part of the global investment bank, released the report Wednesday titled "Sugar: Consumption at a Crossroads," which explores the medical, economic, consumer, corporate and public policy elements of global sugar consumption and what it means for investors.

July 15, 2013

Self-reported medication adherence rates increased among Type 2 diabetes patients using a mobile app, the maker of the app said Monday.

HAIFA, Israel — Self-reported medication adherence rates increased among Type 2 diabetes patients using a mobile app, the maker of the app said Monday.

MediSafe Project said it reviewed adherence rates among Type 2 diabetic users of its app, finding compliance rates at least 26% higher than the generate rate for long-term diabetes therapies, which the World Health Organization reports as 50%. A January 2013 study of the app, which the company launched in November 2012, found similar rates.

June 10, 2013

Low-calorie sweeteners can be used to prevent and manage Type 2 diabetes, according to a new study.

ATLANTA — Low-calorie sweeteners can be used to prevent and manage Type 2 diabetes, according to a new study.

The study, conducted by a group of researchers at the Baylor College of Medicine and published in the summer 2013 issue of the journal U.S. Endocrinology, examined the role between excess weight gain and management and prevention of Type 2 diabetes from available literature.

July 23, 2012

Extended use of the oral DPP-4 inhibitor linagliptin to lower blood-glucose levels by Type 2 diabetes patients is effective, according to a new study.

NEW YORK — Extended use of the oral DPP-4 inhibitor linagliptin to lower blood-glucose levels by Type 2 diabetes patients is effective, according to a new study.

A team of eight researchers — four of which work for drug maker Boehringer Ingelheim — examined 2,121 Type 2 diabetes patients that had taken part in four previous 24-week randomized, double-blind, placebo-controlled trials in order to monitor them for a further 78 weeks. The participants who took part in the extended trial came from 231 sites in 32 countries.

July 2, 2012

Bristol-Myers Squibb is acquiring Amylin Pharmaceuticals, the drug maker said Friday.

NEW YORK — Bristol-Myers Squibb is acquiring Amylin Pharmaceuticals, the drug maker said Friday.

Bristol announced that it would acquire Amylin for $5.3 billion, or $31 per share. The total value of the acquisition is about $7 billion, including $1.7 billion in Amylin's contractual payment and debt obligations.

March 26, 2012

Lifestyle intervention and treatment with metformin provide safe, long-term, cost-effective means of preventing Type 2 diabetes and should be incorporated into prevention strategies for reducing the dramatic rise in incidence of Type 2 diabetes in the United States, according to two new analyses and an editorial published in the April issue of Diabetes Care.

ALEXANDRIA, Va. — Lifestyle intervention and treatment with metformin provide safe, long-term, cost-effective means of preventing Type 2 diabetes and should be incorporated into prevention strategies for reducing the dramatic rise in incidence of Type 2 diabetes in the United States, according to two new analyses and an editorial published in the April issue of Diabetes Care.

March 26, 2012

A drug under development by Forest Labs and Pierre Fabre has been shown to reduce symptoms of major depressive disorder, the companies said.

SUPPLIER NEWS — A drug under development by Forest Labs and Pierre Fabre has been shown to reduce symptoms of major depressive disorder, the companies said. New York-based Forest and Paris-based Pierre Fabre announced results of a phase-3 trial of levomilnacipran, saying the drug showed reductions in symptoms as early as one week after treatment was started. The companies expect results of another phase-3 trial of the drug this spring.


 

March 8, 2012

The market for drugs to treat diabetes — especially Type 2 diabetes — has shown quite a bit of activity lately.

The market for drugs to treat diabetes — especially Type 2 diabetes — has shown quite a bit of activity lately. At the end of January, the Food and Drug Administration approved Bydureon (exenatide), a once-weekly version of the drug Byetta, which was originally developed by Alkermes and subsequently developed further under an alliance between Amylin Pharmaceuticals and Eli Lilly that the two companies formed in 2002. In November 2011, however, Amylin and Lilly terminated their alliance in the wake of an announced diabetes drug partnership between Lilly and Boehringer Ingelheim.

February 13, 2012

Amylin Pharmaceuticals and Alkermes announced that their Type 2 diabetes treatment now is available by prescription in U.S. pharmacies.

SAN DIEGO — Amylin Pharmaceuticals and Alkermes announced that their Type 2 diabetes treatment now is available by prescription in U.S. pharmacies.

Bydureon (exenatide extended-release for injectable suspension) received approval from the Food and Drug Administration on Jan. 27 as an adjunct to diet and exercise to improve glycemic control in adults with Type 2 diabetes.

February 3, 2012

Endocrinologists would prescribe a newly approved weekly treatment for Type 2 diabetes to one-fifth of their patients, a new survey showed.

BURLINGTON, Mass. — Endocrinologists would prescribe a newly approved weekly treatment for Type 2 diabetes to one-fifth of their patients, a new survey showed.

February 2, 2012

The Food and Drug Administration has approved a drug made by Merck for Type 2 diabetes, the drug maker said Thursday.

WHITEHOUSE STATION, N.J. — The Food and Drug Administration has approved a drug made by Merck for Type 2 diabetes, the drug maker said Thursday.

Merck announced the approval of Janumet XR (sitagliptin and metformin hydrochloride) extended-release tablets as a once-daily treatment for the disease.

January 30, 2012

The Food and Drug Administration has approved a long-acting injected diabetes drug made by Amylin Pharmaceuticals and Alkermes, the two companies said.

SAN DIEGO — The Food and Drug Administration has approved a long-acting injected diabetes drug made by Amylin Pharmaceuticals and Alkermes, the two companies said.

The FDA approved Bydureon (exenatide), which the companies called the first once-weekly treatment for Type 2 diabetes. The drug will become available in February.

January 11, 2012

A special focus on its diabetes franchise will define Amylin Pharmaceuticals' corporate strategy, the company's chief executive said at a recent conference sponsored by J.P. Morgan.

SAN DIEGO — A special focus on its diabetes franchise will define Amylin Pharmaceuticals' corporate strategy, the company's chief executive said at a recent conference sponsored by J.P. Morgan.

December 8, 2011

A drug currently under clinical development for Type 2 diabetes produced "meaningful" reductions in blood sugar, according to results of a late-stage clinical study.

INDIANAPOLIS — A drug currently under clinical development for Type 2 diabetes produced "meaningful" reductions in blood sugar, according to results of a late-stage clinical study.

Eli Lilly & Co. and Boehringer Ingelheim announced results of a 24-week, open-label arm of a phase-3 study of the investigational drug linagliptin combined with the generic drug metformin, presenting results at the International Diabetes Federation World Diabetes Conference in Dubai.

October 14, 2011

Two classes of drugs for treating Type 2 diabetes will experience the biggest growth in market share of all classes of drugs for the condition, according to a new study by Decision Resources.

BURLINGTON, Mass. — Two classes of drugs for treating Type 2 diabetes will experience the biggest growth in market share of all classes of drugs for the condition, according to a new study by Decision Resources.

The study found that DPP-IV inhibitors and GLP-1 analogues would experience the biggest growth in market share among all drug classes, with a combined market share that will increase from 20% in 2010 to 47% in 2020 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

October 11, 2011

The recent film “Contagion” depicts the world descending to chaos due to the spread of an extremely deadly virus. But in reality, one of the most serious epidemics doesn’t come from an infectious agent but from people’s life choices.


The recent film “Contagion” depicts the world descending to chaos due to the spread of an extremely deadly virus. But in reality, one of the most serious epidemics doesn’t come from an infectious agent but from people’s life choices.


September 16, 2011

A drug made by Boehringer Ingelheim and Eli Lilly showed "meaningful and durable" reductions in blood sugar in adults with Type 2 diabetes, according to results of a late-stage clinical trial presented Friday at a conference in Europe.

LISBON, Portugal — A drug made by Boehringer Ingelheim and Eli Lilly showed "meaningful and durable" reductions in blood sugar in adults with Type 2 diabetes, according to results of a late-stage clinical trial presented Friday at a conference in Europe.

September 13, 2011

An insulin analogue made by Sanofi appears to work better in certain cases than competing treatments at reducing weight gain and controlling blood sugar among patients with Type 2 diabetes.

PARIS — An insulin analogue made by Sanofi appears to work better in certain cases than competing treatments at reducing weight gain and controlling blood sugar among patients with Type 2 diabetes.

September 12, 2011

Patients treated with a long-acting drug for Type 2 diabetes experienced a reduction in cardiovascular health risk factors, according to results of a study presented at the European Association for the Study of Diabetes' annual meeting.

LISBON, Portugal — Patients treated with a long-acting drug for Type 2 diabetes experienced a reduction in cardiovascular health risk factors, according to results of a study presented at the European Association for the Study of Diabetes' annual meeting.

September 8, 2011

Boehringer Ingelheim and Eli Lilly will present data from their diabetes portfolio at the 47th Annual Meeting of the European Association for the Study of Diabetes in Lisbon, Portugal.

RIDGEFIELD, Conn., and INDIANAPOLIS — Boehringer Ingelheim and Eli Lilly will present data from their diabetes portfolio at the 47th Annual Meeting of the European Association for the Study of Diabetes in Lisbon, Portugal.

August 8, 2011

Boston Therapeutics is seeking approval for a generic version of a pill for Type 2 diabetes, the drug maker said.

MANCHESTER, N.H. — Boston Therapeutics is seeking approval for a generic version of a pill for Type 2 diabetes, the drug maker said.

Boston Therapeutics announced that it had filed an application with the Food and Drug Administration for chewable metformin tablets. The drug is a version of Bristol-Myers Squibb's Glucophage.